Publication: 2155

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism That Increases Risk of Docetaxel-Induced Neuropathy
      QxMD      Google Scholar   
Citation:
Clin Cancer Res vol 22 (19) 4890-900
Year:
2016
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
6
Parents:
949   996  
Children:
None
Program:
TRP
Primary Committee:
PPP
Sec. Committees:
   
Pharmas:
Genentech  
Grants:
U10 CA047577, P30 NR014129, U01 GM061393, U10 CA180802, U10 CA021115, U10 CA031946, U10 CA033601, U10 CA180821, P30 CA008748, U10 CA180791, U10 CA180857, U01 GM061390, U10 CA016116, R01 NS064015, U10 CA180820, U10 CA180867, U10 CA180838  
Corr. Author:
 
Authors:
                                                                 
Networks:
CA824, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MD017, LAPS-MN026, LAPS-NC007, LAPS-NY016, NC002   
Study
CALGB-60404
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-90401
Phases:
N/A, 3
Keywords:
docetaxel, paclitaxel, pharmacogenetics, genome-wide association study, heritability, single nucleotide polymorphism, chemotherapy-induced peripheral neuropathy, VAC14, peripheral neuronal cell model, animal model